Clinical Trials

66 enrolled

Breast Neoplasms

NCT07045311 2026-04-15

JS207 Combination Therapy in Triple-negative Breast Cancer

80 enrolled

Triple Negative Breast Neoplasms

NCT07076485 2026-04-15

Shortening Adjuvant Photon and Proton Irradiation (SAPPHIRe-II): A 4 Cohort, Randomized, Phase II Multi-center Trial Evaluating Shorter Schedules of Adjuvant Regional Nodal Irradiation Among Women and Men With Node-positive and High-risk Node-negative Invasive Breast Cancer

768 enrolled

Breast Neoplasms

NCT03412877 2026-04-14

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

BreastEndocrineGynecologicNETPlasma cellThoracic

285 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Multiple Myeloma, Ovarian Neoplasms, Urogenital Neoplasms, Neuroendocrine Tumors

NCT04677816 2026-04-14

Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients

50 enrolled

Vitamin D Deficiency, Triple Negative Breast Neoplasms

NCT04920708 2026-04-14

FAIM

57 enrolled

Breast Neoplasms

NCT07443943 2026-04-14

AIMSS-RPS

20 enrolled

Breast Carcinoma In Situ

NCT07527806 2026-04-14

Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging

156 enrolled

Breast Neoplasms

NCT07528768 2026-04-14

Gemcitabine vs Paclitaxel in Caribbean Women of African Ancestry With Metastatic Triple-Negative Breast Cancer

750 enrolled

Triple Negative Breast Neoplasms

NCT07528898 2026-04-14

Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study.

100 enrolled

Breast Neoplasms

NCT02311933 2026-04-13

Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer

81 enrolled 9 charts

Breast Neoplasms

NCT02398773 2026-04-13

FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy

99 enrolled

HER2/Neu Negative

NCT02465060 2026-04-13

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

6,452 enrolled 2 FDA

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT02630693 2026-04-13

Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer

Phase 2 Completed

180 enrolled 14 charts

Breast Neoplasms

NCT02883062 2026-04-13

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

67 enrolled 16 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02928978 2026-04-13

TBCRC042

Phase 2 Completed

84 enrolled

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating

NCT03598257 2026-04-13

Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer

300 enrolled

Inflammatory Breast Neoplasms

NCT03650894 2026-04-13

Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients

30 enrolled

Breast Neoplasms

NCT04090398 2026-04-13

Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones

70 enrolled

BreastOther neoplasm

Anatomic Stage IV Breast Cancer AJCC v8

NCT04225117 2026-04-13

A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

BreastGastrointestinalHead & NeckThoracic

329 enrolled 23 charts

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Triple Negative Breast Neoplasms

NCT04550494 2026-04-13

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

BreastGastrointestinalGenitourinaryGynecologic

36 enrolled

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

NCT04553133 2026-04-13

PF-07104091 as a Single Agent and in Combination Therapy

BreastGynecologicThoracic

157 enrolled

Breast Neoplasms, Ovarian Neoplasms, Small Cell Lung Carcinoma

NCT04768426 2026-04-13

Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer

40 enrolled

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT05837455 2026-04-13

NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer

81 enrolled

Breast Neoplasms

NCT05941520 2026-04-13

Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer

80 enrolled

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT06067503 2026-04-13

Biomarkers to Detect Endocrine Therapy Resistance

8 enrolled

Breast Neoplasms, Neoplastic Cells, Circulating, Neoplasm Metastasis, Carcinoma, Lobular

NCT06184750 2026-04-13

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

200 enrolled

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT06195306 2026-04-13

Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction

66 enrolled

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT06810804 2026-04-13

A Phase IIa Study to Evaluate NBQ72S

10 enrolled

Breast Neoplasms

NCT07007559 2026-04-13

ASPEN-09-03

120 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT07069595 2026-04-13

PREDICT-RD

78 enrolled

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT07162051 2026-04-13

A Study on the Use of Fluzoparib Combined With Chemotherapy for Neoadjuvant Treatment of HRD-positive, HR+/HER2- Breast Cancer

Phase 2 Completed

28 enrolled

Breast Neoplasms

NCT07340541 2026-04-13

EVOLVE-BDT

700 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07368998 2026-04-13

optINAVO

80 enrolled

Breast Neoplasms

NCT07523607 2026-04-13

FAP PET/CT for Staging Patients With Breast Cancer

65 enrolled

Breast Neoplasms

NCT04841148 2026-04-09

PALAVY

96 enrolled

Breast Neoplasms, Neoplasm, Residual

NCT06695845 2026-04-09

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors